Prognostic value of event‐free survival at 12 and 24 months and long‐term mortality for non‐Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group

Abstract

EFS12 and EFS24 predict an early increase in mortality. The long-term SMR, over the course of 10 years of follow-up, shows that patients with FL have a risk of dying similar to that of a sex- and age-matched general population. Cancer 2017;123:3709-3716. © 2017 American Cancer Society.

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

“…Several recent observations indicate that response to initial treatment along with the achievement of a strong and durable response may favorably affect long-term outcome. 31,[40][41][42][43][44] The present update clearly demonstrates in a prospective study that CR achievement shows the strongest association with prolonged survival. The importance of the response depth for long-term survival is confirmed by our molecular monitoring of measurable residual disease (MRD) performed in a subset of patients.…”

Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma

“…In comparison, achieving event-free survival for 1 to 2 years is associated with low failure risk and excellent outcomes in other lymphomas primarily treated with chemotherapy. 44 , 45 , 46 , 47 The survival landmark variations may reflect the heterogeneous clinical behaviors after different curative therapies. Consistent with conditional analysis for other malignant tumors in the curative context, 26 , 27 , 28 , 29 improved survival and decreased hazards of failure and mortality over time highlight the long-term curability of radiotherapy for early-stage NKTCL.…”

Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma

“…These indices do not reliably predict early therapeutic failure, defined as relapse within 2 years of treatment with immunochemotherapy (IC) . Conversely, patients who achieve event‐free survival (EFS) at 24 months (EFS24) have no added mortality beyond the background population . We currently lack full understanding of the factors contributing to this discrepancy in outcomes and there is a need to better identify these high‐risk patients at diagnosis to potentially guide therapeutic decisions …”